Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Telegram Restored on Apple App Store After Temporary Removal 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
DURHAM, N.C., April 02, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that Garrett Nichols, M.D., M.S., Chief Medical Officer of Chimerix will present at the H.C. Wainwright Annual Global Life Sciences Conference on Monday, April 9, 2018 at 10:15 a.m. CET at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
Michelle LaSpaluto
(919) 972-7115
[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
[email protected]
413-478-2003
